Treatment of steroid-naive ulcerative colitis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 9, 2009, Pages 1449-1460

  Bossa, Fabrizio ^a   Colombo, Elisabetta ^a   Andriulli, Angelo ^a   Annese, Vito ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Safety; Steroids; Therapy; Ulcerative colitis

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDENOFALK; BUDESONIDE; CORTICOSTEROID; CORTISONE; CYTOKINE; DEXAMETHASONE SODIUM PHOSPHATE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TETRACYCLINE;

ACNE; ALOPECIA; ATHEROSCLEROSIS; BACTERIAL INFECTION; BEHAVIOR DISORDER; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EDEMA; ELECTROLYTE BALANCE; ENDOCRINE DISEASE; ERYTHROCYTE; EYE DISEASE; FLUID BALANCE; FRACTURE; GASTROINTESTINAL DISEASE; GLAUCOMA; GLUCOSE INTOLERANCE; HEADACHE; HEART FUNCTION; HIRSUTISM; HUMAN; HYPERTENSION; INFECTION; KIDNEY FUNCTION; MENTAL DISEASE; MOOD DISORDER; MOON FACE; MUSCULOSKELETAL DISEASE; MYOPATHY; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PSYCHOSIS; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN DISEASE; SKIN INFECTION; SLEEP DISORDER; STEROID THERAPY; T LYMPHOCYTE ACTIVATION; TINNITUS; ULCERATIVE COLITIS; VERTIGO; VIRUS INFECTION; WEIGHT CHANGE; WEIGHT GAIN;

ANIMALS; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEROIDS; TREATMENT OUTCOME;

EID: 67650682066     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902973728     Document Type: Review

References (106)

1. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007;8:171-178
2. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62 (Pubitemid 351179488)
3. Farrel RJ, Kelleher D. Mechanisms of steroid action and resistance in inflammation. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339-346
4. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutical trial. Br Med J 1955;2:1041-1048
5. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260 (Pubitemid 32729372)
6. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-years UK inception cohort. Aliment Pharmacol Ther 2006;24:319-330 (Pubitemid 43972900)
7. Beato M, Herrlich P, Schutz G. mSteroid hormone receptors: many actors in search of a plot. Cell 1995;83:851-857 (Pubitemid 26006527)
8. Scheinman RI, Cogwell PC, Lofquist AK, et al. Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-286
9. Mulder CJJ, Fockens P, Meijer JWR, et al. Beclomethasone Dipropionate (3 mg) vs 5-aminosalicylic acid (2 g) vs the combination of both (3 mg/2 g) as retention enema in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-553 (Pubitemid 26229963)
10. Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007;26:21-29 (Pubitemid 46889839)
11. Lennard-Joned JE, Longmore AJ, Newell AC, etal. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colotis. Gut 1960;1:217-222
12. Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004;20:143-149
13. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Br Med J 1962;2(5302):441-443
14. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-987 (Pubitemid 43374543)
15. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979;77:847-869 (Pubitemid 9242048)
16. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose ranging study. Canadian inflammatory bowel disease study group. Gastroenterology 1996;110:45-51 (Pubitemid 26021603)
17. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003;4:CD000301
18. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part I: short term prognosis. Gut 1963;4:300-308
19. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definition and diagnosis. J Crohns Colitis 2008;2:1-28 (Pubitemid 351179487)
20. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular, and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5-36
21. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-1070
22. Truelove SC, Willoughbly CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-1088 (Pubitemid 9052873)
23. Turner D, Walsh C, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-110 (Pubitemid 46096828)
24. Chakravarty B. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993;88:852-855 (Pubitemid 23181868)
25. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-910 (Pubitemid 26231777)
26. Lindgren S, Flood L, Kilander A, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-835 (Pubitemid 28493257)
27. Benazzato L, D'Inca R, Grigoletto F, et al. Prognosis of severe attacks in ulcerative colitis. Effects of intensive medical treatment. Dig Liv Dis 2004;36:461-466
28. Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007;102:601-608 (Pubitemid 46328134)
29. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-422 (Pubitemid 47187355)
30. Rutter M, Saunders B, Wilkinson KH, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-459 (Pubitemid 38182302)
31. Rutter M, Saunders B, Wilkinson KH, et al. Cancer surveillance in long-standing ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53:1813-1816 (Pubitemid 39556902)
32. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-amynosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53 (Pubitemid 41820634)
33. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476 (Pubitemid 41770166)
34. Odze R, Antonioli D, Peppercorn M, et al. Effect of topycal 5-aminosalicylic acid (5-ASA) therapy on rectal mucosa biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993;17:869-875 (Pubitemid 23245919)
35. Danielsson A, Hellers G, Lyrenas A, et al. A controlled randomised trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987;22:987-992 (Pubitemid 17152840)
36. Löfberg R, Ostergaard-Thomsen O, Langholz E, etal. Budesonide versus prednisolone retention enema in active distal ulcerative colitis. Aliment Pharmacol Ther 1994;8:326-329
37. da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-293
38. Singleton JW, Law DH, Kelley ML, et al. National Cooperative Crohn's disease study: adverse reactions to study drugs. Gastroenterology 1979;77:870-882 (Pubitemid 9242049)
39. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105-111 (Pubitemid 30098773)
40. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000
41. Hoes NJ, Jacobs JWG, Verstappen SMM, et al. Adverse events of low-to-medium dose oral glucocorticoids in inflammatory disease: a meta-analysis. Ann Rheum Dis [Epub 2008 Dec 9]
42. Campieri M, Adamo S, Valpiani D, et al. Oral Beclometasone dipropionate in the treatment of extensive and left-sided ulcerative colitis: a multicenter randomised study. Aliment Pharmacol Ther 2003;17:1471-1480 (Pubitemid 36831438)
43. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of Budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-845 (Pubitemid 24289711)
44. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide study group. Gastroenterology 1998;115:834-840
45. Kolkman JJ, Möllmann HW, Möllmann AC, etal. Evaluation of oral budesonide in the treatment of active ulcerative colitis. Drugs Today 2004;40:589-601
46. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsule (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-1754 (Pubitemid 34761401)
47. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40 (Pubitemid 34747523)
48. Thomas GA, Rhodes J, Ragunath K, et al. Transdermal nicotine compared with oral prednisone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1998;8:769-776
49. Hawthorne AB, Record CO, Holdsworth CD, etal. Double blind trial of oral fluticasone propionate vs prednisolone in the treatment of active ulcerative colitis. Gut 1993;34:125-128
50. Sandborn WJ, Löfbergr R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-1787 (Pubitemid 41648434)
51. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630
52. Fidder HH, Schnitzler F, Ferrante M, et al. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2009;58:501-508
53. Subramanian V, Saxena S, Kang JY, et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008;103:2373-2381
54. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-364
55. Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis 1999;5:200-211
56. Lichtenstein GR, Sands BE, Pazanias M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:797-813 (Pubitemid 44253764)
57. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J 1975;51:20-25
58. Steed KP, Hooper G, Ventura P, et al. The invivo behaviour of a colonic delivery system: a pilot study in man. Int J Pharm 1994;112:199-206 (Pubitemid 24319836)
59. Edsbäcker S, Andersson T. Pharmacokinetics of Budesonide (EntocortTM EC) capsules for Crohn's disease. Clin Pharmacokinet 2004;43:803-821 (Pubitemid 39382221)
60. Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:591-603 (Pubitemid 28329337)
61. Rizzello F, Gionchetti P, Galeazzi R, et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther 2001;18:261-271 (Pubitemid 34117282)
62. Rizzello F, Gionchetti P, D'Arienzo A, et al. Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: a bouble-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109-1116 (Pubitemid 34680753)
63. Löfberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive or left-sided ulcerative colitis. Gastroenterology 1996;110:1713-1718 (Pubitemid 26169207)
64. Kolkman JJ, Mollmann HW, Mollmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today 2004;40:589-601 (Pubitemid 39281176)
65. Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn's disease: a metanalysis. Aliment Pharmacol Ther 2000;14:1419-1428 (Pubitemid 30944721)
66. Seow CH, Benchimol EL, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;16:CD000296
67. Benchimol EL, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;21:CD002913
68. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and non-steroid therapy. Am J Gastroenterol 2002;97:915-921 (Pubitemid 34408248)
69. Magnani M, Rossi L, D'Ascenzo M, et al. Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem 1998;28:1-6 (Pubitemid 28369899)
70. D'Ascenzo M, Antonelli A, Chiarantini L, et al. Red blood cells as glucocorticoids delivery system. In: Sprandel U, Way JL, editors, Erythrocytes as Drug Carriers in Medicine. New York, NY: Plenum Press, 1997. p. 81-87
71. Crinelli R, Antonelli A, Bianchi M, et al. Selective inhibition of NF-kB activation and TNF-α production in macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cells Mol Dis 2000;26:211-222 (Pubitemid 30694704)
72. Rossi L, Serafini S, Cenerini L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol Appl Biochem 2001;33:85-89 (Pubitemid 32304285)
73. Rossi L, Castro M, D'Orio F, et al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol Dis 2004;33:57-63 (Pubitemid 38829599)
74. Annese V, Latiano A, Rossi L, et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study. Am J Gastroenterol 2005;100:1370-1375 (Pubitemid 40904364)
75. Bossa F, Latiano A, Rossi L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild to moderate ulcerative colitis, refractory to mesalamine: a randomized controlled study. Am J Gastroenterol 2008;103:2509-2516
76. Castro M, Rossi L, Papadatou B, et al. Long-term treatment with autologous red blood cells loaded with dexamethasone 21 phosphate in pediatric patients affected by steroid-dependent Crohn's disease. J Pediatr Gastroenterol Nutr 2007;44:423-426 (Pubitemid 46573223)
77. Munkholm P, Langholz E, Hollander D, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362 (Pubitemid 24092906)
78. Hearing SD, Norman M, Probert CS, et al. Predicting therapeutic outcome in severe ulcerative colitis by measuring invitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999;45:382-388 (Pubitemid 29400714)
79. Corrigan CJ. Glucocorticoid-resistant asthma. Tymocytes defects. Am J Clin Care Med 1996;154:553-555
80. Kirkham BW, Corkill MM, Davidson SC, Panayi GS. Response to glucocorticoid treatment in rheumatoid arthritis: invitro cell mediated immune assay predict invivo response. J Rheumatol 1991;18:821-825
81. Langhoff E, Ladefoged J, Jacobsen BK, et al. Recipient lymphocytes sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet 1986;1:1296-1297 (Pubitemid 16114049)
82. Evans WE, McLeod H. Pharmacogenomics - drug disposition, drug targets, and side effect. N Engl J Med 2003;348:538-549 (Pubitemid 36159890)
83. Farrell FJ, Murphy A, Long A, etal. High Multidrug Resistance (P-glycoprotein-170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-288
84. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorhisms and pharmacological impacto in MDR-1, MRP-1 and MRP-2 genes. Pharmacogenomics 2001;2:51-64 (Pubitemid 32633651)
85. Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 2003;6:71-84 (Pubitemid 36565766)
86. Ishikawa T, Onishi Y, Hirano H, et al. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (p-glycoprotein/MDR1). Biol Pharm Bull 2004;27:939-948 (Pubitemid 41701737)
87. Hoffmeyer S, Burk O, von Ritcher O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity invivo. Proc Nat Acad Sci USA 2000;97:3473-3478 (Pubitemid 30183327)
88. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR-1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199 (Pubitemid 32777772)
89. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR1) gene. J Pharmacol Exp Ther 2001;297:1137-1143 (Pubitemid 32472514)
90. Goto M, Masuda S, Saito H, etal. C3435T polymorphism in the MDR-1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living donor-liver transplantation. Pharmacogenetics 2002;12:451-457
91. Illmer T, Schuler US, Thiede C, et al. MDR-1 gene polymorphisms affect therapy outcome in acute myeloid leukaemia patients. Cancer Res 2002;62:4955-4962 (Pubitemid 34984419)
92. Palmieri O, Latiano A, Valvano MR, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther 2005;22:1129-1138 (Pubitemid 41779521)
93. Ardizzone S, Maconi G, Bianchi V, et al. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm Bowel Dis 2007;13:516-523 (Pubitemid 46799634)
94. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behaviour in ulcerative colitis. Gastroenterology 2005;128:288-296 (Pubitemid 40431082)
95. Cucchiara S, Latiano A, Palmieri O, et al. Polymorphisms of tumor necrosis factor alfa but not MDR-1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:171-179 (Pubitemid 46175068)
96. Annese V, Valvano MR, Palmieri O, et al. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006;12:3636-3644 (Pubitemid 43950939)
97. Flood L, Löfberg R, Stierna P, Wikström AC. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticoid therapy. Inflamm Bowel Dis 2001;7:202-209 (Pubitemid 32776512)
98. Raddatz D, Middel P, Bockemuhl M, et al. Glucocorticoid receptor expression in inflammatory bowel disease: an evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis. Aliment Pharmacol Ther 2004;19:47-61 (Pubitemid 38125637)
99. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859-866 (Pubitemid 30243749)
100. Towers R, Naftali T, Gabay G, et al. High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance. Clin Exp Immunol 2005;141:357-362 (Pubitemid 41003360)
101. Bantel H, Domschke W, Schulze-osthoff K. Molecular mechanisms of glucocorticoid resistance. Gastroenterology 2000;119:1178-1179
102. Bantel H, Domschke W, Schulze-Osthoff K, et al. Abnormal activation of transcription Factor NF-kB involved in steroid-resistance in chronic inflammatory bowel disease. Am J Gastroenterol 2000;95:1845-1846 (Pubitemid 30485038)
103. Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol 2004;18:577-596 (Pubitemid 38667468)
104. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alfa promoter on transcriptional activity. Proc Natl Acad Sci USA 1997;94:3195-3199 (Pubitemid 27157287)
105. Sycora J, Subrt I, Didek P, etal. Cytokine tumor necrosic factor alpha promoter gene polymorphism at position -308G?A and pediatric inflammatory bowel disease: implication in ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr 2006;42:479-487 (Pubitemid 43804724)
106. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenaghen, Denmark. Inflamm Bowel Dis 2007;13:481-489